UPDATE 1-Teva says Actavis deal to close by April as profit falls
* Q4 adjusted EPS $1.32 vs $1.29 forecast
* Q4 revenue $4.88 bln vs $4.84 bln forecast
* Generic drug prices fell about 5 pct in 2015
* Sees Q1 adjusted EPS $1.32-$1.36, revenue $4.7-$4.9 bln (Adds Teva comments, details from conference call)
By Tova Cohen
TEL AVIV, Feb 11 (Reuters) - Teva Pharmaceutical Industries , the world's largest generics drugmaker, reported a fall in fourth-quarter profit and revenue on lower sales of its top drug and said it expects to close its purchase of Actavis by early April.
Israel-based Teva agreed last year to buy Allergan's Actavis generic business for $40.5 billion as well as Mexico's Rimsa for $2.3 billion.
Teva had expected to close the Actavis deal by the end of the first quarter though Siggi Olafsson, CEO of global generic medicines, said that could slip into early April as the anti-trust review proceeds.
"We remain confident in completing the transaction and haven't had any surprises during the process," he told a conference call, noting Teva is working with four to five potential buyers in divesting certain assets. Continuación...